Use of biomarkers to detect breast cancer
    1.
    发明申请
    Use of biomarkers to detect breast cancer 审中-公开
    使用生物标志物检测乳腺癌

    公开(公告)号:US20050170352A1

    公开(公告)日:2005-08-04

    申请号:US10506725

    申请日:2003-03-06

    IPC分类号: G01N33/574 C12Q1/68

    CPC分类号: G01N33/57415

    摘要: The present invention relates to a method for identification of tmor biomarkers markers for breast cancer, with high specificity and sensitivity. Preferred methods of the invention include qualifying breast cancer status in a subject comprising: (a) measuring at least one of the disclosed biomarkers in a sample from the subject; and (b) correlating the measurement with breast cancer status. The invention further relates to kits for qualifying breast cancer status in a subject.

    摘要翻译: 本发明涉及一种具有高特异性和灵敏度的用于鉴定乳腺癌组织标记物的标记物的方法。 本发明的优选方法包括在受试者中确定乳腺癌状态,包括:(a)测量来自受试者的样品中所公开的生物标志物中的至少一种; 和(b)将测量与乳腺癌状态相关联。 本发明还涉及用于在受试者中鉴定乳腺癌状态的试剂盒。

    Identification of biomarkers for detecting prostate cancer
    2.
    发明申请
    Identification of biomarkers for detecting prostate cancer 审中-公开
    识别前列腺癌的生物标志物

    公开(公告)号:US20050176011A1

    公开(公告)日:2005-08-11

    申请号:US10512731

    申请日:2003-04-25

    IPC分类号: C12Q1/68 G01N33/00 G01N33/574

    摘要: The present invention relates to a method of qualifying prostate cancer status in a subject comprising: (a) measuring at least one of the disclosed biomarkers in a sample from the subject and (b) correlating the measurement with prostate cancer status. The invention further relates to kits for qualifying prostate cancer status in a subject.

    摘要翻译: 本发明涉及一种在受试者中鉴定前列腺癌状态的方法,包括:(a)测量来自受试者的样品中所公开的生物标志物中的至少一种和(b)将测量与前列腺癌状态相关联。 本发明还涉及用于在受试者中鉴定前列腺癌状态的试剂盒。

    Biomarker for ovarian cancer
    5.
    发明申请
    Biomarker for ovarian cancer 审中-公开
    卵巢癌生物标志物

    公开(公告)号:US20070172902A1

    公开(公告)日:2007-07-26

    申请号:US11473280

    申请日:2006-06-21

    IPC分类号: G01N33/574 G06F19/00

    CPC分类号: G01N33/57449 G01N2333/52

    摘要: The present invention provides a protein-based biomarker that is useful in qualifying ovarian cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarker can be detected by SELDI mass spectrometry.

    摘要翻译: 本发明提供了一种可用于鉴定患者卵巢癌状态的基于蛋白质的生物标志物。 特别地,本发明的生物标志物可用于将受试者样品分类为卵巢癌或非卵巢癌。 可通过SELDI质谱法检测生物标志物。

    Biomarker for ovarian and endometrial cancer: hepcidin
    6.
    发明申请
    Biomarker for ovarian and endometrial cancer: hepcidin 有权
    卵巢和子宫内膜癌的生物标记物:铁调素

    公开(公告)号:US20070054329A1

    公开(公告)日:2007-03-08

    申请号:US11373833

    申请日:2006-03-10

    IPC分类号: G01N33/574

    摘要: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.

    摘要翻译: 本发明提供了可用于鉴定卵巢癌状态以及患者中子宫内膜癌状态的基于蛋白质的生物标志物和生物标志物组合。 特别地,已经发现,铁调素是卵巢癌和子宫内膜癌的生物标志物,并且一组生物标志物,包括铁调素,转甲状腺素蛋白和任选的其他标记物可用于将受试者样品分类为卵巢癌或非卵巢癌。 生物标志物可以通过SELDI质谱检测。

    Biomarkers for detecting ovarian cancer
    7.
    发明申请
    Biomarkers for detecting ovarian cancer 审中-公开
    用于检测卵巢癌的生物标志物

    公开(公告)号:US20050214760A1

    公开(公告)日:2005-09-29

    申请号:US10500838

    申请日:2003-01-07

    IPC分类号: C12Q1/68 G01N33/574

    CPC分类号: C12Q1/6886 G01N33/57449

    摘要: New biomarkers are provided that are useful for detecting cancer in a patient sample, particularly ovarian cancer. In a preferred aspect, methods for qualifying ovarian cancer status in a subject are provided that comprises measuring at least one of Markers I through VII in a sample from the subject, and correlating the measurement with ovarian cancer status.

    摘要翻译: 提供了新的生物标志物,其可用于检测患者样品中的癌症,特别是卵巢癌。 在一个优选的方面,提供了在受试者中鉴定卵巢癌状态的方法,其包括在受试者的样品中测量至少一种标志物I至VII,并将测量与卵巢癌状态相关联。